Literature DB >> 1828975

Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies.

A Laquerriere1, G Raguenez-Viotte, M Paraire, J P Bizzari, M Paresy, J P Fillastre, J Hemet.   

Abstract

Chloroethylnitrosoureas are reactive compounds that are highly effective against malignant neoplasms in humans and animals. The most widely used nitrosoureas, lomustine and carmustine, are known to be hepatotoxic and to induce pericholangitis and intrahepatic cholestasis, which in the long term lead to cholangiolysis and biliary cirrhosis. However, the nitrosourea fotemustine has proved to be non-hepatotoxic at 20 mg/kg and 50 mg/kg. We have studied the effect of these three nitrosoureas on the cytotoxicity and cellular kinetics of rat liver cells. Lomustine and carmustine modify the proliferation index of liver cells in vivo: flow cytofluorometry showed that DNA cell distribution is quite similar for lomustine and carmustine, with subsequent accumulation of cells in G2 + M phase. 3 months later regressive morphological and cell cycle perturbations are noted for the lower dose of lomustine and carmustine. The most severe lesions are noted with lomustine (50 mg/kg). Fotemustine is not hepatotoxic and preferentially induces S phase perturbations. The more toxic nitrosoureas, lomustine and carmustine, induce comparable hepatocyte cell cycle alterations which differ from those induced by the less hepatotoxic nitrosourea fotemustine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828975     DOI: 10.1016/0277-5379(91)90232-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.

Authors:  Johannes E A Wolff; Su Berrak; Susannah E Koontz Webb; Ming Zhang
Journal:  J Neurooncol       Date:  2008-02-06       Impact factor: 4.130

2.  Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.

Authors:  Gaetano Corazzelli; Ferdinando Frigeri; Manuela Arcamone; Luigi Aloj; Gaetana Capobianco; Cristina Becchimanzi; Emanuela Morelli; Francesco Volzone; Gianpaolo Marcacci; Filippo Russo; Rosaria De Filippi; Secondo Lastoria; Antonio Pinto
Journal:  Eur J Haematol       Date:  2011-07-31       Impact factor: 2.997

Review 3.  An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.

Authors:  Giuseppe Lombardi; Patrizia Farina; Alessandro Della Puppa; Diego Cecchin; Ardi Pambuku; Luisa Bellu; Vittorina Zagonel
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.